Lowest Price Guaranteed
Pages
345
Last Updated
May 2026
View Count
18653
The global radiopharmaceutical manufacturing market is estimated to grow from $3.7 billion in 2024 to $9.0 billion by 2035, representing a CAGR of 8.44% during the forecast period till 2035.
 |
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, partnerships and collaborations analysis, market impact analysis, gap assessment framework, market forecast and opportunity analysis. The radiopharmaceutical manufacturing market growth over the next decade is likely to be the result of rising prevalence of chronic diseases, ongoing technological advancements and rise in the demand for targeted radionuclide therapy.
Nuclear medicine is a medical specialty that involves the use of radiopharmaceuticals or radiotracers in which radioisotopes are bound to biological molecules that can target specific organs, tissues, or cells within the human body. Over the past few years, radiopharmaceuticals have been extensively used for various diagnostic and therapeutic procedures owing to their very short half life, specificity to targets and high affinity.
Currently, over 50 radiopharmaceuticals have been approved across the world, for the diagnosis and treatment of a myriad of chronic diseases, including infectious diseases, immunological disorders, gastroenteric diseases, cardiovascular disorders, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by World Nuclear Association, more than 10,000 hospitals, worldwide, claim to use radioisotopes for various diagnostic and therapeutic procedures.
 |
 |
 |
It is worth highlighting that around 40 million diagnostic procedures are conducted, annually, which specifically utilize only one radioisotope, Technitium-99m. Typically, diagnostic tests are performed by using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). Further, the introduction of the concept of theranostics, which involves the usage of a single active ingredient for both diagnostic and therapeutic purposes, has opened a new era in patient centric treatment approach.
It is important to note that the development and production of radiopharmaceuticals is fraught with several challenges, including shortage of production capacity, complex manufacturing process, lack of skilled labor and stringent guidelines mandated by regulatory agencies. This has prompted the drug developers to outsource certain key operations (specifically the complex manufacturing processes) to contract service providers, which further helps to reduce cost and expediate the launch of their radioactive drug products to the market. Owing to the increasing research activity and ongoing technological advancements in the field of radiopharmaceuticals, along with the growing burden of chronic diseases, the radiopharmaceutical manufacturing market is anticipated to witness exponential market growth during the forecast period.
 |
 |
 |
The market report presents an in-depth analysis of the various companies that are engaged in the radiopharmaceutical production, across different segments, as defined in the table below:
| Key Report Attribute | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | 10+ Years | |
| Future Trend | Till 2035 | |
| Market Size, 2024 | $ 3.7 Billion | |
| CAGR | 8.4% | |
| Application Area |
|
|
| Type of Diagnostic Radiopharmaceutical |
|
|
| Type of Therapeutic Radiopharmaceutical |
|
|
| Type of Radioisotope |
|
|
| Purpose of Manufacturing |
|
|
| Source of Manufacturing |
|
|
| Scale of Operation |
|
|
| Therapeutic Area |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
(Full list of 95+ companies and 115+ non-industry players captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the radiopharmaceutical production market, over the forecast period. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate for the market evolution during the forecast period till 2035.
The market report also features the likely distribution of the current and forecasted opportunity within the radiopharmaceutical manufacturing market based on various parameters, such as application area (diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals), type of diagnostic radiopharmaceutical (Positron Emission Tomography radiopharmaceuticals and SPECT radiopharmaceuticals), type of therapeutic radiopharmaceutical (alpha emitters, beta emitters and other therapeutic radiopharmaceuticals), type of radioisotope (Technetium-99m, Fluorine-18, Leutetium-177, Gallium-68, Actinium-225 and other radioisotopes), purpose of manufacturing (contract manufacturing and in-house manufacturing), source of manufacturing (nuclear reactors and cyclotrons), scale of operation, therapeutic area and key geographical regions.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry stakeholders:
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
According to our market report, the diagnostic radiopharmaceuticals hold the largest share (61%) of the market. This dominance is driven by the growing usage of PET and SPECT imaging in early-stage oncology and cardiology, where Technetium-99m remains the primary isotope for the treatment. In addition, the expansion of diagnostic centers in emerging markets and the increasing clinical reliance on molecular imaging provide a predictable, long-term revenue stream with high barriers to entry.
In the upcoming years, therapeutic radiopharmaceuticals is likely to grow at higher CAGR of 17.4% during the forecast period. This lucrative growth is propelled by the theranostics revolution and the success of targeted ligands, such as Lutetium-177 and Actinium-225, which are transforming end-stage cancer treatment.
On the basis of our analysis, SPECT radiopharmaceuticals’ segment is expected to hold a dominant 78% of the market share. This largest share is likely due to the high clinical volume of Technetium-99m procedures, which remain the global gold standard for cardiac stress testing and bone scans due to lower equipment costs and a robust, generator-based supply chain. SPECT represents a resilient, asset class with significant barrier-to-entry advantages in emerging markets, where the affordability and portability of SPECT cameras drive the majority of diagnostic throughput.
On the other hand, the PET radiopharmaceuticals segment is projected to expand at a higher CAGR during the forecast period. This growth is fueled by PET’s superior spatial resolution and the clinical shift toward F-18 and Ga-68 tracers for precise oncology staging and Alzheimer’s diagnostics. Market players are considering it as a high-growth technology, as the rapid installation of hospital-based cyclotrons and the "theranostic pairing" of PET tracers with new therapeutics create an immediate demand for advanced manufacturing sites capable of handling short-lived isotopes.
According to our radiopharmaceutical manufacturing market, the beta emitters segment holds the highest share (65%) of the market. This highest share is due to the widespread adoption of Lutetium-177 and Yttrium-90, which are the primary isotopes for treating high-prevalence conditions, such as neuroendocrine tumors and prostate cancer. Companies that control high-purity Lutetium supplies and possess integrated cold-chain logistics hold a major advantage in this segment, serving as the high-yield utility players of precision oncology.
On the other hand, alpha emitters segment is expected to register a higher CAGR of 18.7% during the forecast period. This growth is likely to be the result of unique high-energy, short-range nature of Actinium-225 and Lead-212, which provide a "last-line" solution for metastatic cancers resistant to traditional therapies. Currently, the demand of therapeutic radiopharmaceutical is higher than the global supply of alpha-emitting isotopes. Owing to the exceeding demand, massive valuation premiums are being awarded to firms that secure proprietary production methods or exclusive isotope off-take agreements.
The Technetium-99m (Tc-99m) and Fluorine-18 (F-18) isotopes collectively dominate the market. This highest share is fueled by its increasing use of radioisotopes in oncology. For market players, Technetium-99m (Tc-99m) and Fluorine-18 (F-18) offer a balanced infrastructure strategy. Tc-99m provides a stable, high-volume baseline, while F-18 taps into the rapid modernization of diagnostic centers and expanding manufacturing networks.
In the upcoming years, Actinium-225 (Ac-225) is likely to grow at a higher CAGR during the forecast period. This highest growth is driven by the fact that Ac-225 is the new frontier due to its potency in targeted alpha therapy (TAT) for radioresistant cancers. This presents a scarcity-driven opportunity to the market players as clinical demand is exceeding the current production capacity, significant valuation premiums are being concentrated in companies that control proprietary accelerator-based production or long-term supply agreements for these next-generation isotopes.
According to our projection, the in-house manufacturing segment holds the highest share of the market. This dominance is due to the fact that large pharmaceutical firms maintain strict, hour-by-hour control over their supply chains to manage the rapid radioactive decay of isotopes like F-18 and Ga-68.
On the other hand, the contract manufacturing (CDMO) segment is likely to register higher CAGR during the forecast period. This growth is driven by a wave of biotech startups and pharmaceutical companies that lack the capital for nuclear-grade infrastructure, choosing instead to outsource complex radiochemistry to specialized partners. Moreover, the specialized CDMOs are focusing on providing the technical expertise and regulatory licensing required to bring next-generation alpha and beta therapies to market, which further support the highest CAGR of this region.
On the basis of our market report, the nuclear reactor segment holds the highest share of the market. This dominance is due to the fact that nuclear reactors are the essential source for long-lived isotopes and major therapeutic beta-emitters, such as Lutetium-177 and Technetium-99m generators, which require centralized, high-flux neutron irradiation. In addition, the aging global fleet of research reactors and the high barriers to entry posed by stringent nuclear regulatory oversight and the massive capital expenditure required for reactor-based infrastructure.
On the other hand, the cyclotron segment is projected to grow at a higher CAGR during the forecast period. This surge is driven by the shift toward decentralized production of short-lived PET isotopes, such as Fluorine-18 and Gallium-68, which can be manufactured on-site or in regional centers closer to patients. In addition, cyclotron is aa high-alpha technology with lower initial investment requirements, reduced radioactive waste profiles, and the ability to produce high-specific-activity isotopes are the essential reasons that are supporting the global expansion of precision molecular imaging.
Based on our analysis, the commercial scale segment dominates the market. This highest share is driven by the high-volume diagnostic isotopes, such as Technetium-99m and the accelerated approval of blockbuster therapeutics, such as Pluvicto, which require standardized, large-batch production to reach thousands of patients monthly.
In the future, the preclinical segment is likely to register the highest CAGR during the forecast period. This growth is fueled by the increase in clinical trials, particularly for targeted alpha therapies and new neurological PET tracers that require flexible, small-batch manufacturing. This trend presents a strong investment opportunity. Because large pharmaceutical companies want to buy clinical-stage assets to build their future portfolios, manufacturing sites built for quick, small-scale production will further accelerate the growth of this segment.
According to our analysis, the oncological disorders segment dominates the market. This highest share is driven by the global prevalence of prostate, lung, and breast cancers, where radiopharmaceuticals have become the standard for both precise PET/SPECT staging and targeted treatments using isotopies, such as Lutetium-177. As cancer cases continue to increase, companies with proprietary ligands and large-scale oncology manufacturing hubs are capturing massive valuation premiums by addressing a non-discretionary and expanding patient pool.
On the other hand, the neurological disorders segment is expected to grow at a higher CAGR during the forecast period. This lucrative growth is due to the growing shift towards molecular imaging for early Alzheimer’s and Parkinson’s detection, especially with the recent approvals of amyloid-targeting PET tracers.
Based on regional analysis, North America region dominates the market, anticipated to hold 50% of the overall revenue share. This dominance is driven by a advanced healthcare ecosystem, high R&D investment, and favorable reimbursement policies that accelerate the adoption of high-priced targeted therapies. In addition, the presence of leading players and a mature regulatory framework (FDA) provides a clear path for commercializing high-margin innovations, such as theranostic ligands.
In the future, Asia-Pacific region is projected to expand at a high CAGR during the forecast period. This rapid growth is fueled by massive infrastructure investments in China and India, including a surge in regional cyclotron facilities and the localization of isotope production to mitigate import reliance. In addition, the convergence of an aging population and government-led nuclear medicine programs is creating an unprecedented demand for diagnostic and therapeutic capacity in previously underserved urban centers.
The “Radiopharmaceutical Manufacturing Market: Industry Trends and Global Forecasts, till 2035” report features an extensive study of the current market landscape, market size and future opportunities associated with the radiopharmaceutical production market, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the radiopharmaceutical production industry. Key takeaways of the radiopharmaceutical manufacturing market report are briefly discussed below.
With the increasing global geriatric population, the incidence of several chronic diseases, such as cancer, cardiovascular disorders and diabetes are expected to rise. It is worth highlighting that cancer has emerged as a leading cause of death, with an estimated 10 million people succumbing to the disease annually. According to a report by the World Heart Federation, global deaths from cardiovascular disorders have increased from 12.1 million in 1990 to 20.5 million in 2021. Further, it is estimated that by 2050, chronic diseases will account for 86% of the 90 million annual deaths. This has led to a rise in the demand for effective diagnosis and treatment options for patients suffering from these diseases.
The current market landscape features the presence of over 215 industry and non-industry players that are engaged in the production of a variety of radiopharmaceuticals, including Positron Emission Tomography radiopharmaceuticals, SPECT radiopharmaceuticals, alpha emitters and beta emitters. Further, for the production of such radiopharmaceuticals, more than 190 manufacturing facilities have been established by these industry players, across different geographical regions. Additionally, the radiopharmaceutical manufacturing market research report features the presence of small, mid-sized, large, and very large companies having the required expertise to offer contract manufacturing services across the globe.
In addition, the companies in this domain have undertaken several initiatives, such as entering into partnerships, and expanding their existing capabilities and capacities, in order to cater to the increasing demand for radiopharmaceuticals. It is worth noting that, in May 2023, Fusion Pharmaceuticals, a US based drug developer established a cGMP facility in Ontario, Canada for the production of next generation targeted alpha therapies.
Companies engaged in radiopharmaceutical manufacturing have forged several partnerships in order to enhance their product and service portfolio. The growing preference for outsourcing radiopharmaceutical production operation is evident from the rise in partnership activity in the radiopharmaceutical manufacturing market. It is worth highlighting that, since 2019, over 270 strategic partnerships have been inked in the nuclear medicine and radiopharmaceutical manufacturing domain.
Notably, majority of the deals are focused on the supplying radioisotopes, followed by instances of mergers and acquisitions. It is worth highlighting that in January 2024, Eli Lilly and Company acquired Point Biopharma for USD 1.4 billion, in order to advance next-generation radioligand therapies for the treatment of various cancers . Further, in November 2023, Telix Pharmaceuticals, a mid-sized company acquired Lightpoint Medical for USD 35 million. This acquisition aligns with Telix's strategic vision to enhance its offerings and advance innovation in medical imaging technologies. We believe that such acquisitions in the radiopharmaceutical domain will drive the market growth during the forecast period.
The radiopharmaceutical manufacturing market growth can be attributed to the ever-increasing demand for advanced therapeutic modalities for the treatment of various chronic diseases. It is worth highlighting that more than 200 clinical trials are currently underway to investigate several radiotherapeutics for the treatment of a wide range of diseases, across different geographies. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. The anticipated success of these drugs is likely to act as an impetus to the growth of overall radiopharmaceutical manufacturing market.
It is important to note that radiopharmaceuticals are highly complex and have a very short half life, and require advanced technologies, expertise and manufacturing facilities for their production, which are available with contract manufacturers. Therefore, in recent years, an increased inclination of drug developers towards outsourcing complex manufacturing operations has been observed, which is unlikely to change in the future.
The global radiopharmaceutical production market is estimated to be worth USD 3.7 billion in 2024. The radiopharmaceutical manufacturing market growth is expected to be driven by the growing incidence of chronic diseases and rising demand for therapeutic modalities leading to a CAGR of 8.4%.
As the demand for radiopharmaceuticals is increasing, a number of big pharmaceutical companies are also entering this market, providing the necessary impetus for growth. Owing to the future potential in this market, numerous radiopharmacies have begun to offer contract development and manufacturing services for radiopharmaceuticals.
Presently, 50% of the overall radiopharmaceutical production market is captured by North America. Further, it is worth highlighting that, owing to the rising demand for diagnostic and therapeutic radiopharmaceuticals, growing population, increasing incidence of chronic diseases and advancements in diagnostic imaging technology, market in Asia-Pacific is likely to grow at a higher CAGR as compared to other regions in the coming years.
Examples of leading manufactures involved in the radiopharmaceutical manufacturing market (which have also been captured in this market report, arranged in alphabetical order) include Advanced Accelerator Applications, Applied Molecular Therapies, Cardinal Health, DuChemBio, Eckert & Ziegler, Evergreen Theragnostics, Isotopia Molecular Imaging, ITM Isotope Technologies Munich, Nihon Medi-Physics, Nucleus RadioPharma, PentixaPharm, PharmaLogic, RadioMedix, SOFIE and Telix Pharmaceuticals. This global market research report on radiopharmaceutical manufacturing includes an easily searchable excel database including all the companies that we identified are engaged in manufacturing of radiopharmaceuticals worldwide.
 |
 |
 |
Several recent developments have taken place in the field of radiopharmaceutical manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.